Compare Dolby Laboratories, Inc. (DLB) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs 22nd Century Group Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.95 (market cap $5.75B), while 22nd Century Group Inc trades at $4.38 (market cap $1.52M). The key difference: Dolby Laboratories, Inc. is far larger — about 3782.9× 22nd Century Group Inc's market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| DLB | XXII | |
|---|---|---|
Market Cap | $5.75B | $1.52M |
Sector | Industrials | Technology |
52-Week High | $75.62 | $801.00 |
52-Week Low | $48.51 | $3.72 |
Enterprise Value | $5.12B | -$6.71M |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $60.74, down 2.19% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with an 87.61% gross margin and has beaten EPS estimates for four consecutive quarters. Recent news highlights innovation in automotive and broadcast licensing, though revenue growth remains choppy.
The stock presents a compelling opportunity with a consensus price target of $87.50, implying significant upside, but faces near-term execution risks and licensing volatility. Long-term growth drivers in premium audio/visual formats are balanced by macroeconomic sensitivity and competitive pressures.
XXII trades at $4.46, up 2.53% today, with a neutral technical signal and bearish moving averages. The company shows deep losses with a net income margin of -65.76% and negative ROE of -130.19%, though it beat earnings in Q3 2025. Recent news highlights VLN® retail expansion in California and New York, and a reverse stock split on June 12, 2026. Cash flow remains dependent on financing, with operating cash flow negative at -$7.72 million in 2025.
Outlook is speculative; analyst consensus is 75% buy with growth potential from VLN® market expansion, but high execution and regulatory risks persist. Investment hinges on revenue scaling to offset persistent losses, with stock volatility expected near key resistance at $5.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
